Best Growth Stocks to Buy for September 25th

Zacks highlighted Petco (WOOF), Five Below (FIVE), and Oscar Health (OSCR) as Zacks Rank #1 stocks, citing upward current-year earnings-estimate revisions of 26.3%, 15.2%, and 210.2%, respectively, over the past 60 days. The article is a stock-selection screen rather than company-specific fundamental news, so its likely market impact is limited despite the favorable analyst-revision signals.

Analysis

This is a low-information sell-side ranking signal rather than a fundamental catalyst; the relevant question is whether estimate changes reflect durable operating revisions or merely a catch-up after prior guidance. WOOF and FIVE are most exposed to discretionary-demand volatility, where a single quarter of traffic or gross-margin disappointment can erase the benefit of higher consensus EPS. The positive read-through is therefore more useful as a screening flag into earnings than as a reason to chase either stock immediately.

For WOOF, the investable issue is whether veterinary/services mix and inventory discipline can sustain margin recovery despite promotional intensity from Chewy (CHWY), Walmart (WMT), Amazon (AMZN), and mass retail. For FIVE, the key second-order risk is that a value-retail narrative can mask store-level execution issues: wage, shrink, freight, and new-store productivity matter more to the multiple than modest near-term EPS revisions. A consumer-spending slowdown could favor FIVE's price-point positioning, but only if it preserves transaction growth rather than forcing heavier markdowns.

OSCR has the cleanest earnings-revision setup but also the highest policy and medical-cost sensitivity. The market will reward evidence that pricing, risk adjustment, and administrative-cost leverage are improving simultaneously; a medical-loss-ratio increase or adverse ACA/regulatory development would compress the growth multiple quickly. QBTS has no clear fundamental linkage to the cited screening signal and should not be treated as a read-through.

Contrarian view: crowded attention to upward estimates often arrives after the first leg of repricing. The better risk/reward is to wait for corroboration in next-quarter guidance, same-store/traffic data for retail, and medical-cost commentary for OSCR; absent those, this is not sufficient evidence of a durable earnings inflection.

Key Decisions for Investors

• No broad directional trade on the ranking signal alone; revisit WOOF, FIVE, and OSCR only after the next earnings release confirms raised full-year guidance rather than consensus-only revisions.
• Watch-list long OSCR over a 1-3 month horizon if management reaffirms or raises profitability guidance while medical-cost trends remain controlled; use a position size reflecting binary regulatory/MLR risk. Falsify on a material medical-loss-ratio deterioration or reduced EBITDA/earnings outlook.
• Potential pair: long FIVE / short a higher-end discretionary retail basket (for example XRT selectively hedged with exposure to specialty apparel) only if consumer data weaken while FIVE maintains traffic and merchandise-margin guidance. Exit if comparable-sales guidance turns negative or markdown commentary accelerates.
• Avoid chasing WOOF until evidence of sustained gross-margin and services-mix improvement appears. A long is more compelling after confirmation that promotional activity is not rising; falsify on renewed price competition from CHWY/AMZN or a cut to EBITDA guidance.
• Exclude QBTS from this thesis; its inclusion appears unrelated to the operating drivers of WOOF, FIVE, or OSCR and creates unnecessary thematic noise.